ZE66-0205 / Eilean Therapeutics - LARVOL DELTA

A First-in-Human Study of ZE66-0205 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=32 | Not yet recruiting | Sponsor: Eilean Therapeutics

First-in-human • New P1 trial

Development of ZE66-0205, a Novel MALT1 Degrader for Treatment of B-Cell Malignancies (ASH 2024) - "Interestingly, TMD8 cell lines CRISPR-edited to exclusively express BTK mutations seen with non-covalent (pirtobrutinib) T474I or covalent (acalabrutinib or zanubrutinib) C481S BTK inhibitors responded similarly to ZE66-0205. ZE66-0205 leads to on target degradation of CBM target proteins and represents a promising new treatment strategy for DLBCL and other B-cell malignancies. Future clinical development of ZE66-0205 is warranted and ongoing."

B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CARD11 • CD79B • CRBN • IL2 • MALT1 • MYD88

Eilean Therapeutics Presents First-in-Class MALT1 Degrader TE205 Demonstrating In Vivo Efficacy in Ulcerative Colitis at the 4th International Conference on Microbiology and Immunology (PRNewswire) - "In preclinical studies, TE205 demonstrated a robust and multifaceted immunomodulatory effect in the DSS-induced colitis model, achieving both structural and functional restoration of intestinal integrity....Collectively, these results establish TE205 as a potent, first-in-class MALT1 degrader with strong in vivo efficacy and clear disease-modifying potential for inflammatory bowel disease (IBD)."

Preclinical • Inflammatory Bowel Disease • Ulcerative Colitis